TY - JOUR
T1 - Relationship between cell-mediated immunity to Varicella–Zoster virus and aging in subjects from the community-based Shozu Herpes Zoster study
AU - for the SHEZ study group
AU - Shirane, Risako
AU - Tang, Huamin
AU - Hayashi, Kenichi
AU - Okuno, Yoshinobu
AU - Iso, Hiroyasu
AU - Asada, Hideo
AU - Yamanishi, Koichi
AU - Mori, Yasuko
N1 - Publisher Copyright:
© 2016 Wiley Periodicals, Inc.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Age-related declines in cell-mediated immunity (CMI) are associated with the incidence and severity of Herpes Zoster (HZ) infection. However, the level of Varicella–Zoster virus (VZV)-specific CMI associated with disease onset is unclear. This study aimed to examine factors associated with VZV-specific CMI, as measured by an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assay, in a Japanese cohort. The study enrolled 365 subjects aged 60 years and over, all of whom were taking part in the Shozu Herpes Zoster (SHEZ) study and had undergone four sets of blood and intradermal reaction tests during a 3 year follow-up period. The VZV-specific immunity profile of each subject was assessed, and linear mixed effects models were constructed to analyze IFN-γ ELISPOT results in association with a combination of factors. The model that best explained the IFN-γ ELISPOT results was selected using the Akaike Information Criteria. The best-fit model consisted of age group as the only explanatory fixed-effect variable. The model showed that VZV-specific CMI, quantified as numbers of spots on the ELISPOT assay, among subjects aged 70–79 was on average 10.30 points lower than that among subjects aged 60–69. There was no statistically significant difference between subjects aged 70–79 and those aged 80–89. Age was the only factor significantly associated with the level of VZV-specific CMI, as measured by the IFN-γ ELISPOT assay. These results may represent an important step towards quantifying the relationship between VZV-specific CMI and the onset of HZ. J. Med. Virol. 89:313–317, 2017.
AB - Age-related declines in cell-mediated immunity (CMI) are associated with the incidence and severity of Herpes Zoster (HZ) infection. However, the level of Varicella–Zoster virus (VZV)-specific CMI associated with disease onset is unclear. This study aimed to examine factors associated with VZV-specific CMI, as measured by an interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assay, in a Japanese cohort. The study enrolled 365 subjects aged 60 years and over, all of whom were taking part in the Shozu Herpes Zoster (SHEZ) study and had undergone four sets of blood and intradermal reaction tests during a 3 year follow-up period. The VZV-specific immunity profile of each subject was assessed, and linear mixed effects models were constructed to analyze IFN-γ ELISPOT results in association with a combination of factors. The model that best explained the IFN-γ ELISPOT results was selected using the Akaike Information Criteria. The best-fit model consisted of age group as the only explanatory fixed-effect variable. The model showed that VZV-specific CMI, quantified as numbers of spots on the ELISPOT assay, among subjects aged 70–79 was on average 10.30 points lower than that among subjects aged 60–69. There was no statistically significant difference between subjects aged 70–79 and those aged 80–89. Age was the only factor significantly associated with the level of VZV-specific CMI, as measured by the IFN-γ ELISPOT assay. These results may represent an important step towards quantifying the relationship between VZV-specific CMI and the onset of HZ. J. Med. Virol. 89:313–317, 2017.
KW - Herpes Zoster
KW - Varicella–Zoster virus
KW - cell-mediated immunity
KW - epidemiology
KW - immune responses
KW - immunity/immunization
KW - virus classification
UR - http://www.scopus.com/inward/record.url?scp=84989271237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989271237&partnerID=8YFLogxK
U2 - 10.1002/jmv.24629
DO - 10.1002/jmv.24629
M3 - Article
C2 - 27420414
AN - SCOPUS:84989271237
SN - 0146-6615
VL - 89
SP - 313
EP - 317
JO - Journal of Medical Virology
JF - Journal of Medical Virology
IS - 2
ER -